Brensocatib – complimentary MARA Rating report: pricing & reimbursement risk assessment for non-cystic fibrosis bronchiectasis.
Brensocatib has undergone evaluation through the MARA Rating framework to assess its market-access prospects for non-cystic fibrosis bronchiectasis. The overall MARA Score is 2.42 out of 4. This corresponds to a Marginal (B++) rating. This is below both the 5-year therapeutic-area average for respiratory drugs (3.0) and the industry-wide 5-year average (3.0). This indicates a comparatively weaker access profile.
Clinical Effectiveness: Strong but Not Transformative
The Phase 2 WILLOW trial demonstrated a 42% reduction in exacerbation risk relative to placebo. The Phase 3 ASPEN trial confirmed sustained benefits over 52 weeks. It showed a 19–21% reduction in exacerbation rates.
These findings establish clinical benefit, though the magnitude of effect remains smaller than that observed with existing options such as macrolides.
Comparator Selection: Appropriate
Trial design employed placebo plus standard care, an appropriate choice given the absence of approved preventive therapies for exacerbations in bronchiectasis. This approach reflects real-world practice and allows results to be interpreted with confidence.
Care-Pathway Integration: Strong Alignment
Brensocatib shows strong alignment with current treatment strategies. The drug can be added to established protocols without introducing new diagnostic requirements or major workflow disruptions. It is positioned as an adjunctive therapy for patients with frequent exacerbations, fitting neatly into existing care models.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.